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The reaction mechanism of DNA topoisomerase II (TOP2) involves a covalent double-strand break
intermediate in which the enzyme is coupled to DNA via a 50-phosphotyrosyl bond. This normally tran-
sient enzyme-bridged break is stabilised by drugs such as mitoxantrone, mAMSA, etoposide, doxorubicin,
epirubicin and idarubicin, which are referred to as TOP2 poisons. Removal of topoisomerase II by the
proteasome is involved in the repair of these lesions. In K562 cells, inhibiting the proteasome with
MG132 significantly potentiated the growth inhibition by these six drugs that target topoisomerase II,
and the highest level of potentiation was observed with mitoxantrone. Mitoxantrone also showed the
greatest potentiation by MG132 in three Nalm 6 cell lines with differing levels of TOP2A or TOP2B.
Mitoxantrone was also potentiated by the clinically used proteasome inhibitor PS341 (Velcade). We have
also shown that proteasome inhibition with MG132 in K562 cells reduces the rate of removal
of mitoxantrone or etoposide stabilised topoisomerase complexes from DNA, suggesting a possible
mechanism for the potentiation of topoisomerase II drugs by proteasomal inhibition.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Type II DNA topoisomerases (TOP2s) play a role in several cellu-
lar processes including replication, transcription, chromosome
condensation and segregation and permit the alteration of DNA
topology by allowing one double-stranded DNA segment to pass
through another. They achieve this by introducing an enzyme-
bridged double-strand break into the first DNA segment, where
each monomer of the dimeric enzyme remains covalently attached
to the ends of the DSB via a 50-phosphotyrosyl linkage. The second
DNA segment is then ‘‘passed” through the enzyme-bridged DNA
gate, and the break is re-ligated. The enzyme-bridged gate is nor-
mally a short lived intermediate, but a group of drugs, known as
‘‘TOP2 poisons” inhibit the religation step resulting in the forma-
tion of an unusual type of DSB in which the TOP2 protein remains
covalently linked to the DNA. These breaks are cytotoxic, hence the
utility of TOP2 poisons such as etoposide, epirubicin and
mitoxantrone in cancer therapy. Cells deficient in KU or LIG4 are
extremely sensitive to TOP2 poisons, as are cells treated with the
DNA-PKcs inhibitor NU7026, implicating NHEJ in the repair of
TOP2-induced DSBs [1–6]. However, TOP2-linked DSBs do not
activate DNA-PK in vitro [7] and various lines of evidence suggest
cellular processing is required before TOP2-induced breaks elicit aDNA damage response [8,9]. A number of potential mechanisms
exist to remove TOP2 adducts from DNA to allow repair by NHEJ,
including cleavage by an AP lyase activity such as KU [2,10];
removal of the DNA end bearing the TOP2 by a nuclease such as
MRE11 [11–13] or proteolysis of the TOP2 protein followed by
the action of a 50-tyrosyl DNA phosphodiesterase, TTRAP/TDP2
[14–17].
A number of studies have implicated the proteasome pathway
in regulating TOP2 protein levels, although the precise situation
is complex and probably depends on cell type and the nature of
the stresses that cells are exposed to in different experimental sit-
uations. Two topoisomerase orthologues exist in mammalian cells,
TOP2A and TOP2B [18–20] and both are targeted by topoisomerase
poisons such as etoposide [21]. TOP2A but not TOP2B is degraded
in a cell cycle dependent manner in a way that appears to involve
the ubiquitin–proteasome pathway [22] and TOP2A degradation
has also been observed in a number of conditions that generate
cellular stress, including adenovirus infection, glucose starvation
and oxidative stress [23–27]. The degradation of TOP2A is ubiqui-
tin and ATP dependent, and a number of ubiquitin ligases including
BRCA1, FBW7, MDM2, BMI1/RING1A and ECV have been reported
to associate with TOP2A [26–31]. TOP2 poisons trigger proteasome
dependent decreases in TOP2 protein levels. It has been reported
that etoposide and teniposide trigger reduction of TOP2A and
TOP2B protein [9,28,30,32,33], whilst ICRF-193 (a catalytic inhibi-
tor) triggers proteasome dependent degradation of only TOP2B
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reported to overcome resistance to TOP2 poisons [36,37]. Here
we show that inhibition of the proteasome with MG132 or PS341
potentiates the growth inhibition by some drugs targeting topoiso-
merase II. In addition, we show that in K562 cells proteasomal
inhibition by MG132 reduces the rate of removal of etoposide or
mitoxantrone stabilised covalent topoisomerase II complexes from
the genomic DNA following drug removal from the media.Fig. 1. MG132 dose response in K562 cells. The IC20 of MG132 in K562 cells was
determined by growth inhibition assays. Cells were treated with increasing
concentrations of MG132 and stained with XTT after 5 days of incubation. Error
bars represent the mean ± SEM of 4 separate experiments.2. Material and methods
2.1. Cell lines
The CML cell line K562, the human pre-B cell line Nalm-6 and
the TOP2A+/ and TOP2B/ derivatives of Nalm-6 [38] were cul-
tured in RPMI 1640 medium (Life Technologies, UK) containing
10% foetal bovine serum (Life Technologies, UK) and antibiotics
(Life Technologies, UK). Cells were maintained at 37 C in a humid-
ified atmosphere containing 5% CO2. Nalm-6 and its derivatives
have a normal p53 status [39], whilst K562 is null for p53 [40,41].
2.2. Growth inhibition assays
Cells were seeded in 96 well plates (Greiner-Bio-ONE, UK) and
incubated at 37 C, 5% CO2 for 24 h prior to drug treatment (2000
cells per well for K562 or 10,000 cells per well for Nalm 6 cell
lines). Cells were then treated with varying concentrations of
anti-topoisomerase II drug alone (Sigma Aldrich, UK) or in combi-
nation with the proteasome inhibitor MG132 (Sigma) or PS341
(Cambridge Bioscience, UK) and incubated for 120 h. 50 lL XTT
reagent (50:1 XTT reagent to electron coupling reagent, XTT Cell
Proliferation kit, Roche, UK) was added per well and cells were
incubated for a further 4 h. Absorbance values were obtained using
the Bio-Rad 550 Microplate Reader (Bio-Rad, USA) and analysed
using GraphPad Prism software (GraphPad Software, USA), version
4.03. Growth inhibition values were determined by setting the
values obtained with no drug as 100% for the etoposide-alone data
and with MG132/PS341 alone as 100% for the etoposide plus
MG132/PS341 data.
The IC50 values (concentration at 50% growth inhibition) of anti-
topoisomerase II drug alone versus IC50 of drug in combinationwith
proteasome inhibitor were used to calculate potentiation factors
(Pf50). The inhibitory concentration of TOP2 poison in the presence
of proteasome inhibitor was divided by the concentration of TOP2
poison alone for each separate experiment. The mean Pf50 values
in the tables represent the mean of at least 3 individual Pf50 values.
2.3. In vitro trapped in agarose DNA immunostaining (TARDIS)
TOP2 adducts on genomic DNA were generated by treating
K562 cells with 100 lM etoposide or 5 lM mitoxantrone for 2 h
prior to embedding cells in agarose on microscope slides (Lonza,
USA). To inhibit the proteasome, cells were treated with 50 lM
MG132. Cells were collected at the times shown after drug removal
and TOP2A and TOP2B complexes were quantified by TARDIS
analysis as previously described [42–44]. Briefly, cells were mixed
with molten LMP agarose (Lonza, USA) and spread thinly on slides.
Agarose embedded cells were then extracted with 0.1% SDS and
1 M NaCl leaving ‘‘nuclear ghosts” consisting of genomic DNA cou-
pled to any TOP2 protein-DNA complexes. TOP2 complexes were
then detected by quantitative immunofluorescence from several
fields of cells per slide. Microscopy was carried out using an
Olympus IX81 motorised microscope fitted with an Orca-AG camera
(Hamamatsu) and suitable narrow-band filter sets. Images were
analysed using Volocity software (Perkin-Elmer). Experiments werecarried out at least in triplicate and data are presented as mean
of means obtained for each replicate for each treatment ± SEM.
For the data in Fig. 9A, rabbit polyclonal antibodies 18511a and
18513b were employed [45], and for the data in Figs. 9B and 10,
antibodies 4566-TOP2A and 4555-TOP2B were used. 18511a was
raised in-house to recombinant human TOP2A generated in yeast,
whilst 18513b, 4566-TOP2A and 4555-TOP2B were raised to GST-
TOP2 C-terminal domain fusion proteins generated in bacteria.
2.4. Standard immunofluorescence
Cells were plated in PBS (Life Technologies, UK) onto poly
lysine-coated slides (VWR, UK) and after allowing 10 min for cells
to adhere, they were fixed in PBS containing 4% paraformaldehyde
(Sigma, UK). Immunofluorescence was carried out using rabbit
anti-TOP2A (4566) and mouse anti-TOP2B (MAB6348, R&D
Systems) and Alexa-488 and Alexa-594 coupled anti-rabbit and
anti-mouse secondary antibodies respectively (Life Technologies,
UK) as described [46].
2.5. Western blotting
Cells were washed in ice cold PBS and pelleted in 2 ml
microfuge tubes. Whole-cell extracts were prepared and Western
blotting was performed as described previously [47]. Poly
K48-linked ubiquitin was detected with the rabbit monoclonal
APU2 (Merck-Millipore, UK) [48]. Autorads were quantified using
a GelDoc EX imager (Bio-Rad). Blots were stripped and re-probed
for actin, and APU2 signals were normalised to actin.
3. Results
3.1. The proteasome inhibitor MG132 potentiates the growth
inhibitory effects of anti-topoisomerase II drugs in K562 cells
K562 cells were incubated with a combination of MG132 and
one of six drugs that target DNA topoisomerase II. These included
mitoxantrone, mAMSA and etoposide, (an anthracenedione, an
acridine and an epipodophyllotoxin, respectively), and three
anthracyclines; doxorubicin, its epimer epirubicin, and idarubicin.
In order to investigate whether proteasome inhibition affected the
growth inhibitory effect of these DNA topoisomerase II-targeting
agents, K562 cells were treated with a range of concentrations of
anti-topoisomerase II drug with or without MG132 and growth
inhibition was measured by XTT staining. The concentration of
Table 1
Pf50 values of TOP2 poisons in combination with the proteasome inhibitor MG132 in
K562 cells. Cells were treated with increasing concentrations of TOP2 poison alone or
in combination with 95 nM MG132 for 5 days and stained with XTT reagent. Pf50
values were calculated using the IC50 of TOP2 poison alone and the IC50 of TOP2
poison in combination with MG132. Pf50 values represent the mean of individual Pf50s
from at least 3 separate experiments. p values are a comparison between IC50 of TOP2
poison alone versus the IC50 of TOP2 poison in combination with MG132.
Mean Pf50 SEM p value
Mitoxantrone 4.58 0.54 <0.0001
mAMSA 2.68 0.30 0.0005
Etoposide 1.65 0.25 0.0261
Doxorubicin 1.93 0.31 0.0155
Epirubicin 1.93 0.24 0.0018
Idarubicin 1.92 0.09 0.0018
K.C. Lee et al. / Biochemical Pharmacology 103 (2016) 29–39 31MG132 employed was 95 nM, which on its own resulted in 20%
growth inhibition under the conditions used (Fig. 1). The potentia-
tion of TOP2 poisons by MG132 was considered significant if there
was a statistically significant difference between the IC50 of TOP2
poison alone and the IC50 in the presence of MG132 (as determined
by unpaired t-test). MG132 significantly potentiated growth
inhibition by all six anti-topoisomerase II drugs (Fig. 2A). Potentia-
tion factors (Pf50) were calculated using the IC50 value of
anti-topoisomerase II drug alone over the IC50 value of anti-
topoisomerase II drug in combination with MG132, and are shown
in Table 1. The greatest potentiation was observed with mitox-
antrone and MG132, with a Pf50 of 4.58 (p 6 0.0001). mAMSA
showed the second strongest potentiation with a Pf50 of 2.68
(p = 0.0005). Similar levels of potentiation were observed betweenFig. 2. Potentiation of TOP2 poisons by MG132 in K562 cells. (A) Cells were treated with increasing concentrations of TOP2 poison alone or in combination with 95 nM
MG132 for 5 days followed by XTT staining. Dose–response curves were used to estimate the IC50 of TOP2 poison alone and in combination with MG132. Error bars represent
the mean ± SEM of at least 3 separate experiments for both + andMG132 conditions, values were normalised to the 0 TOP2 poison value (100%). (B) 95 nMMG132 exposure
over 5 days results in accumulation of K48-linked polyubiquitin consistent with compromised proteasome function. K562 cells were treated with MG132 at 95 nM for 5 days
or 10 lM for 2 h. Western blots prepared from whole cell extracts were probed for K48 linked polyubiquitin. Blots representing six replicate treatments were scanned,
densitometry values were normalised to actin and are expressed as a percentage of the mean normalised value obtained for 10 lM MG132.
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epirubicin and idarubicin, respectively). The smallest potentiation
was observed for etoposide with a Pf50 of 1.65, but this was also
statistically significant (p = 0.0261). These data indicate that inhibit-
ing the proteasomal protease with MG132 can potentiate four
classes of drugs that target DNA topoisomerase II. To confirm that
this dose of MG132 affects proteasome function, cells were incu-
bated with 95 nM MG132 for 5 days, and accumulation of
K48-linked polyubiquitin in the cells was determined by Western
blotting with antibody APU2 [48] (Fig. 2B). For comparison, cells
were also incubated with 10 lM MG132 for 2 h. Western blotting
with APU2 antibody resulted in a faint high molecular weight
smear in untreated cells and a much more intense signal in cells
exposed to 10 lM MG132, consistent with proteasomal inhibition
and the resulting accumulation of polyubiquitinated proteins.
Notably, in cells exposed to 95 nM MG132 for 5 days the APU2
signal was also significantly more intense than in control cells, indi-
cating compromised proteasomal function at this dose of inhibitor.
TOP2A and TOP2B protein levels were also measured in K562 cells
following a 5 day incubation with 95 nM MG132 by quantitative
immunofluorescence with rabbit anti-TOP2A (4566) and mouse
anti-TOP2B (MAB6438). MG132 did not induce a change in TOP2A
or TOP2B levels under these conditions, suggesting the observed
potentiation of anti-topoisomerase II drugs by MG132 is not simply
due to an increase in levels of drug target (Fig. 3).Fig. 3. Effect of proteasome inhibitors on cellular TOP2 levels. K562 cells were
seeded and incubated for 24 h, followed by treatment with 95 nMMG132 or 5.2 nM
PS341 alone for 120 h as in the XTT assay. Cells were fixed onto poly lysine slides
with 4% paraformaldehyde and TOP2A and TOP2B levels were quantified by
immunofluorescence. Statistical comparisons were made between proteasome
inhibitor alone and solvent control.3.2. Potentiation of anti-DNA topoisomerase drugs by the proteasome
inhibitor PS341 in K562 cells
The proteasome inhibitor PS341 (bortezomib, Velcade) is used
successfully in the clinic for multiple myeloma and is being trialled
for other haematological malignancies [49]. To determine the
effect of PS341 on the growth inhibitory effects of anti-DNA topoi-
somerase drugs, K562 cells were incubated with one of the above
drugs alone or in combination with PS341. The IC50 values were
determined as before and used to generate the Pf50 values, shown
in Table 2. A fixed dose of 5.2 nM PS341 was used which on its
own results in 20% growth inhibition (Fig. 4). PS341 significantly
reduced the IC50 of mitoxantrone, epirubicin and mAMSA
(p = 0.002, 0.0056 and 0.0259, respectively), but not etoposide,
idarubicin or doxorubicin (p = 0.7690, 0.0890 and 0.1826) (Fig. 5).
Mitoxantrone was potentiated most by PS341 with a Pf50 of 2.95.
Notably, the level of potentiation with PS341 was lower than with
MG132. Although both inhibitors primarily target the b5 subunit of
the proteasome [50], MG132 is less selective than PS341 due to off-
target inhibition of lysosomal cysteine proteases and the calpains
[51]. Therefore, some MG132-mediated potentiation could be
due to inhibition of proteases other than the proteasome. Nonethe-
less, the robust potentiation observed with PS341 and mitox-
antrone, epirubicin or mAMSA indicates that the proteasome is
an important determinant of the sensitivity of cells to these three
TOP2 poisons.
It has been suggested that PS341 reduces resistance to TOP2
poisons by increasing levels of drug target, improving drug efficacy
[37]. To investigate whether the potentiating effect of PS341 is dueTable 2
Pf50 values of TOP2 poisons in combination with the proteasome inhibitor PS341 in
K562 cells. Cells were treated with increasing concentrations of TOP2 poison alone or
in combination with 5.2 nM PS341 for 5 days and stained with XTT reagent. Pf50
values were calculated using the IC50 of TOP2 poison alone and the IC50 of TOP2
poison in combination with PS341. Pf50 values represent the mean of individual Pf50s
from 3 separate experiments. p values are a comparison between IC50 of TOP2 poison
alone versus the IC50 of TOP2 poison in combination with PS341.
Mean Pf50 SEM p value
Mitoxantrone 2.95 0.11 0.002
mAMSA 1.70 0.35 0.0259
Etoposide 1.24 0.32 0.7690
Doxorubicin 1.44 0.23 0.1826
Epirubicin 1.63 0.05 0.0056
Idarubicin 1.37 0.02 0.0890
Fig. 4. PS341 dose response in K562 cells. The IC20 of PS341 in K562 cells was
determined by growth inhibition assays. Cells were treated with increasing
concentrations of PS341 and stained after 5 days of incubation. Error bars represent
the mean ± SEM of 3 separate experiments.
Fig. 5. Potentiation of TOP2 poisons by PS341 in K562 cells. Cells were treated with increasing concentrations of TOP2 poison alone or in combination with 5.2 nM PS341 for
5 days followed by XTT staining. Dose–response curves (where % is inhibition of growth in relation to controls without TOP2 drug) were used to estimate the IC50 of TOP2
poison alone and in combination with PS341. Error bars represent the mean ± SEM of at least 3 separate experiments.
K.C. Lee et al. / Biochemical Pharmacology 103 (2016) 29–39 33to an upregulation of TOP2 levels, K562 cells were incubated with
5.2 nM PS341 for 5 days. TOP2 levels were then measured by quan-
titative immunofluorescence. PS341 induced a significant increase
in TOP2A levels (p = 0.0089) (Fig. 3). This is in contrast to MG132
which did not affect TOP2 levels. Thus, PS341 could potentiate
TOP2 poison activity, at least partly by increasing the cellular level
of TOP2A.3.3. Role of TOP2A and TOP2B isoforms in the potentiation of anti-
topoisomerase drugs by MG132
To examine the role of TOP2A and TOP2B in the potentiation of
anti-topoisomerase II drugs by MG132, growth inhibition assays
were performed using the human pre-B cell line Nalm-6 and the
TOP2A+/ and TOP2B/ derivatives of Nalm-6 [38]. Compared to
WT, Nalm-6 TOP2A expression is reduced to approximately 50%
in Nalm-6TOP2A+/ cells and TOP2B is absent in Nalm-6TOP2B/
cells. Notably, Nalm-6TOP2B/ cells were the most resistant to
mitoxantrone and mAMSA compared to wild-type cells whilst
Nalm-6TOP2A+/ cells were most resistant to etoposide, doxorubicin
and epirubicin. Nalm-6TOP2A+/ and Nalm-6TOP2B/ cells were
equally resistant to idarubicin (Fig. 6). These observations are con-
sistent with those reported by Toyoda et al. [38] and Errington
et al. [52] and support a relatively large role for TOP2B in the
cytotoxic activity of mAMSA and mitoxantrone, and conversely a
larger contribution of TOP2A in the cytotoxicity of etoposide and
doxorubicin (Fig. 6).
For potentiation experiments in each of the Nalm-6 variant lines,
190 nMMG132 was used. This is the IC20 determined for MG132 in
Nalm-6TOP2B/ cells, which did not differ significantly between
the Nalm-6TOP2B/ cell line and that of Nalm-6WT cells or between
Nalm-6TOP2B/ and Nalm-6TOP2A+/ cells (Fig. 7). Co-incubation
with MG132 significantly reduced the IC50 of mitoxantrone,
epirubicin and etoposide in wild type cells (p = 0.0173, 0.0237
and 0.0414, respectively; Fig. 8). As in K562 cells, this potentiation
was greatest in combination with mitoxantrone (Pf50 = 1.94)
(Table 3). Interestingly, the potentiation of mitoxantrone was
reduced (but remained significant) in Nalm-6TOP2A+/ cellscompared to wild type cells, suggesting TOP2A is involved in (but
is not essential for) the potentiation of MTX with MG132. Unlike
in wild type cells, there was no potentiation of etoposide or epiru-
bicin in Nalm-6TOP2A+/ cells, suggesting TOP2A is required for
MG132-mediated potentiation of these two drugs.
There was also no potentiation of etoposide in Nalm-6TOP2B/
cells (p = 0.2560), suggesting a role for TOP2B in the potentiation
of etoposide by MG132, whilst potentiation of epirubicin remained
significant in Nalm-6TOP2B/ cells. In contrast, potentiation of
mitoxantrone still occurred in both Nalm-6TOP2A+/ cells and
Nalm-6TOP2B/ cells. These results indicate that both isoforms
are involved in the potentiation of anti-topoisomerase drugs by
MG132, but the importance of each isoform differs between drugs.
This may be due to the differential levels of TOP2 complexes
formed by different anti-topoisomerase drugs [42].3.4. Proteasomal inhibition affects TOP2-DNA complex reversal
Inhibition of the proteasome is known to reduce resistance to
chemotherapeutic agents by various mechanisms including inhibi-
tion of NFjB activation and cell cycle arrest [53]. In addition the
proteasome plays a role in the processing of TOP2 protein-DNA
complexes in response to TOP2 poisons [8,9,28,32]. We measured
the rate of reversal of etoposide-induced TOP2-DNA complexes in
K562 cells in the presence or absence of the proteasome inhibitor
MG312 (Fig. 9) and the rate of removal of mitoxantrone-induced
TOP2-DNA complexes in K562 cells in the presence or absence of
MG132 (Fig. 10). This was achieved using the TARDIS method
[42–44] where covalent TOP2-DNA complexes are specifically
measured by quantitative immunofluorescence of SDS-salt
extracted agarose embedded cells (see Section 2). K562 cells were
incubated with either etoposide (100 lM) or MG132 (50 lM) and
etoposide (100 lM) concurrently for 2 h. Drug was then washed
out and cells were incubated in fresh medium or fresh medium
containing MG132 to maintain proteasomal inhibition. TOP2
complexes remained at background levels in cells incubated with
MG132 alone (Fig. 9A). When cells were incubated with etoposide,
in the absence of MG132, the initially high TOP2A and TOP2B
Fig. 6. Growth inhibition of Nalm-6 WT, Nalm-6TOP2A+/ and Nalm-6TOP2B/ cells by topoisomerase II poisons. Cells were treated with increasing concentrations of TOP2
poison and dose–response curves (where % is inhibition of growth in relation to untreated controls) were plotted. Error bars represent the mean ± SEM of at least 3 separate
experiments.
Fig. 7. MG132 dose response in Nalm-6 WT, Nalm-6TOP2A+/ and Nalm-6TOP2B/
cells. The IC20 of MG132 in Nalm-6 WT, Nalm-6TOP2A+/ and Nalm-6TOP2B/ cells
was determined by XTT assay. Cells were treated with increasing concentrations of
MG132 and stained after 5 days of incubation. Error bars represent the mean ± SEM
of at least 3 separate experiments.
34 K.C. Lee et al. / Biochemical Pharmacology 103 (2016) 29–39complex levels fell to background within 2 h of drug removal, as
we have previously reported [21]. In the presence of MG132,
although TOP2A fluorescence values initially dropped after etopo-
side removal, complex levels did not return to control levels during
the time of the experiment, and this was statistically significant at
all time points. Similar results were observed for TOP2B (Fig. 9A).
After etoposide washout the persistence of TOP2B complexes in
the presence of MG132 was significant at all time points measured.
During the time course of the experiment cell viability measured
by trypan blue exclusion remained P90% (Fig. 9A). Fig. 9B shows
TOP2A and TOP2B protein levels determined by immunofluores-
cence for the time points used in the TARDIS experiment. There
was a significant reduction in TOP2A protein levels after a 2 h
exposure to etoposide, but this was no longer seen after 2 h in drug
free media. Fig. 9C shows FACS analysis of cell cycle distribution of
the cells at 0 (2 h with etoposide or MG132 or etoposide and
MG132) and 120 min (2 h after removal of etoposide). MG132
alone slightly increased the G2 fraction of cells at both time points,
Fig. 8. Potentiation of TOP2 poisons by MG132 in Nalm-6 WT, Nalm-6TOP2A+/ and Nalm-6TOP2B/ cells. Cells were treated with increasing concentrations of TOP2 poison
alone or in combination with 190 nM MG132 for 5 days followed by XTT staining. Dose–response curves (where % is inhibition of growth in relation to untreated controls)
were used to estimate the IC50 of TOP2 poison alone and in combination with MG132. Error bars represent the mean ± SEM of at least 3 separate experiments.
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Table 3A
TOP2 poison IC50 values alone and in combination with MG132 in Nalm-6 cell lines. Cells were treated with increasing concentrations of TOP2 poison alone or in combination
with 190 nM MG132 for 5 days and stained with XTT reagent. IC50 values represent the mean IC50 from at least 3 separate experiments.
Nalm-6 WT Nalm-6TOPA2+/ Nalm-6TOP2B/
IC50 alone (nM) IC50 with MG132 (nM) IC50 alone (nM) IC50 with MG132 (nM) IC50 alone (nM) IC50 with MG132 (nM)
Mitoxantrone 4.23 2.33 8.67 6.57 17.43 6.10
mAMSA 49.50 39.17 33.92 19.33 152.50 113.08
Etoposide 85.67 59.33 264.33 235.67 156.80 126.60
Doxorubicin 9.43 7.17 23.30 14.00 13.53 9.60
Epirubicin 12.80 7.40 16.10 14.37 12.07 9.03
Idarubicin 3.03 2.87 3.92 3.46 4.77 3.95
Table 3B
Pf50 values of TOP2 poisons in combination with MG132 in Nalm-6 WT, Nalm-6TOP2A+/ and Nalm-6TOP2B/ cells. p values are a comparison between the IC50 of TOP2 poison
alone versus the IC50 of TOP2 poison in combination with MG132. Pf50 values represent the mean of individual Pf50 values from at least 3 separate experiments (MTX n = 3,
mAMSA n = 6, etoposide n = 3, doxorubicin n = 3, epirubicin n = 3, idarubicin n = 6).
Nalm-6 WT Nalm-6TOP2A+/ Nalm-6TOP2B/
Mean Pf50 SEM p value Mean Pf50 SEM p value Mean Pf50 SEM p value
Mitoxantrone 1.94 0.33 0.0173 1.32 0.05 0.0021 2.93 0.35 0.0002
mAMSA 1.29 0.06 0.4554 2.02 0.36 0.0017 1.25 0.12 0.1710
Etoposide 1.46 0.06 0.0414 1.12 0.04 0.1177 1.24 0.18 0.2560
Doxorubicin 1.42 0.36 0.1472 1.73 0.26 0.0560 1.42 0.09 0.0135
Epirubicin 1.88 0.37 0.0237 1.12 0.05 0.1770 1.35 0.08 0.0318
Idarubicin 1.06 0.03 0.3653 1.14 0.07 0.3206 1.25 0.13 0.1717
36 K.C. Lee et al. / Biochemical Pharmacology 103 (2016) 29–39but cell cycle distribution was not significantly altered for other
treatments during the time course of the experiment.
TOP2-DNA complexes stabilised by mitoxantrone have a longer
half-life than those stabilised by etoposide, with TOP2A-DNA
complexes being longer lived than TOP2B-DNA complexes [43].
Therefore, the rate of removal of mitoxantrone stabilised TOP2A-
and TOP2B-DNA complexes was measured up to 24 h and 6 h after
mitoxantrone removal, respectively (Fig. 10). Mitoxantrone was
removed from the cell culture media after 2 h of drug treatment.
In the absence of MG132 TOP2B complexes reduced over time:
more than 50% of the complexes had reversed 6 h after removal
of mitoxantrone, whilst in the presence of MG132 the TOP2B com-
plex levels remained elevated. The proteasome inhibitor resulted
in a significant persistence of TOP2B complexes at 3 and 6 h after
mitoxantrone removal.
In contrast, even in the absence of MG132 the TOP2A complexes
were not reduced at 1, 3 or 6 h. Mitoxantrone-stabilised TOP2A
complexes took 24 h to reduce to less than 50% of the level seen
after 2 h exposure to mitoxantrone. In the presence of MG132,
the TOP2A complex levels remained elevated even at 24 h. This
was statistically significant at 24 h compared to mitoxantrone
alone (p < 0.005).
Thus, MG132 inhibits removal of drug stabilised TOP2-DNA
complexes, confirming the role of the proteasome in the processing
of TOP2 cleavable complexes. The proteasome may facilitate the
removal of TOP2 from the DNA protein complex directly through
degradation of TOP2 (as suggested by previous work), or indirectly
by triggering repair pathways.
4. Discussion
In the current study, we have shown that proteasome inhibition
by MG132 potentiates the growth inhibitory effects of six
anti-topoisomerase II drugs (mitoxantrone, mAMSA, doxorubicin,
epirubicin, idarubicin and etoposide) in K562 cells which are p53
null, and two or three anti-topoisomerase II drugs in Nalm-6 cell
lines which are p53 wild type. In Nalm-6WT cells MG132 potenti-
ated the effect of mitoxantrone, etoposide and epirubicin; in
Nalm-6TOP2B/ cells MG132 potentiated mitoxantrone, epirubicinand doxorubicin, whilst in Nalm-6TOP2A+/ cells MG132 only poten-
tiated mitoxantrone and mAMSA. Differences in the potentiation
by MG132 with different anti-topoisomerase II drugs were
observed. Potentiation of mitoxantrone with MG132 was seen in
all 4 cell lines. This was greatest in K562 and mitoxantrone was
the only agent potentiated in all three Nalm-6 cell lines. Both iso-
forms of TOP2 are targeted by mitoxantrone and it can stabilise
protein-DNA complexes with either isoform [52]. Both isoforms
seem to be required for MG132-mediated potentiation by
etoposide as the differences in IC50 are not significant in
Nalm-6TOP2A+/ or Nalm-6TOP2B/ cells. Both TOP2A and TOP2B
covalent complexes are trapped in response to etoposide [21]. Ours
and other data suggest that TOP2A may be most important for
etoposide-mediated cytotoxicity [38,52] and growth inhibition
(Fig. 7), as Nalm-6TOP2+/ cells are the most resistant to etoposide.
Nonetheless, Nalm-6TOP2B/ cells are also more resistant to etopo-
side than wild type cells, demonstrating TOP2B also plays a role in
etoposide-mediated cytotoxicity.
MG132 inhibited the clearance of TOP2 covalent complexes
stabilised by etoposide or mitoxantrone (Figs. 9 and 10, respec-
tively), increasing the levels of TOP2A and TOP2B covalent com-
plexes. In the absence of MG132 the half-lives of TOP2A and
TOP2B covalent complexes in response to mitoxantrone are 10
and 6 h respectively [52], compared to 30 min and 15 min respec-
tively with etoposide [43]. With etoposide, MG132 increased the
half-lives of TOP2A and TOP2B to >120 min, and with mitox-
antrone increased the half-life of each isoform to >24 h and >6 h
respectively. Thus, proteasome inhibition may potentiate TOP2
poisons by prolonging the half-life of TOP2-DNA complexes and
preventing their repair. In support of this, it has been suggested
that proteasome inhibition prevents the liberation of the TOP2-
mediated DSB [8], which is required for the NHEJ repair of
etoposide-induced DSBs [7]. Our data further support the role of
the proteasome in the processing of TOP2-DNA complexes, which
has been shown for both isoforms [8,9,28] and is consistent with
Sunter et al. [54], who show that levels of TOP2-DNA complexes
are increased by MG132 when compared to etoposide alone.
We also investigated the clinically used proteasome inhibitor
PS341 (bortezomib, Velcade), the first proteasome inhibitor to be
Fig. 9. MG132 inhibits the reversal of etoposide-induced TOP2A- and TOP2B-DNA complexes. (A) K562 cells were incubated with solvent, etoposide (100 lM), MG132
(50 lM) or were co-incubated with 50 lM MG132 and 100 lM etoposide for 2 h. After 2 h etoposide was removed, but MG132 was maintained in cell incubations that
initially contained it. Levels of TOP2A and TOP2B DNA complexes at 0, 15, 30, 60 and 120 min after etoposide removal (wash-out) were determined using the TARDIS assay.
Statistical comparisons were made between the levels of TOP2-DNA complexes in the presence or absence of MG132 by unpaired t-test. Figures are given below for cell
viability (trypan blue exclusion) under the cell treatment conditions used: ‘‘120 min” refers to the time at which drugs were first added to cells, ‘‘0” refers to the time at
which etoposide wash-out was performed and ‘‘120 min” refers to 2 h post drug wash-out. (B) The treatments employed in (A) do not significantly affect cellular TOP2A or
TOP2B levels. Cells were treated as indicated and fixed with paraformaldehyde on poly lysine-coated slides. Total TOP2A and TOP2B was quantified by immunofluorescence.
100 lM etoposide incubation did result in a small decrease in total cellular TOP2A. (C) Cell cycle distribution at time of etoposide wash-out (‘‘0”) and 2 h after etoposide
washout (‘‘120”).
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refractory multiple myeloma and mantle cell lymphoma, which
also shows potential in clinical trials for use in combination with
various chemotherapeutic agents [49]. We found PS341 potenti-
ated the growth inhibition of three TOP2 poisons in K562 cells;
mitoxantrone, mAMSA and epirubicin. We found that incubation
with PS341 for 120 h significantly increased the level of TOP2A,
supporting the suggestion that PS341 increases the sensitivity of
cells to anti-topoisomerase II drugs by increasing levels of TOP2
in the cell, thereby increasing levels of drug target and drug
efficacy [37]. Consistently, PS341 reduces resistance to anti-
topoisomerase II drugs where TOP2 levels are reduced [36].
Notably, MG132 potentiated all six TOP2 poisons tested whilst
PS341 potentiated only three TOP2 poisons. We cannot exclude
that MG132 could potentiate anti-topoisomerase II drugs by othermechanisms. Proteasome inhibition perturbs the ubiquitination of
substrates, leading to the accumulation of ubiquitin conjugates and
the depletion of free ubiquitin [55]. Ubiquitination is important in
the cellular response to DNA damage, co-ordinating the recruit-
ment of DNA repair proteins. This is mediated largely by the E3
ubiquitin ligases RNF8 and RNF168 [56–58]. For example, the
generation of K63-linked ubiquitin chains by RNF168 leads to the
direct recruitment of BRCA1 via the ubiquitin-interacting motif
(UIM) of Rap80 [59]. RNF168 also mediates the monoubiquitina-
tion of histone H2A at lysine 15 which is required for the recruit-
ment of 53BP1 [60]. Importantly, MG132 was shown to inhibit
BRCA1 and 53BP1 foci formation, as well as other key DNA repair
proteins such as Rad51, in response to IR and cisplatin [61].
Therefore, MG132 and PS341 may potentiate the growth inhibitory
effects of anti-topoisomerase II drugs by reducing repair of the
Fig. 10. MG132 inhibits the reversal of mitoxantrone-induced TOP2A- and TOP2B-DNA complexes. K562 cells were incubated with solvent, mitoxantrone (5 lM), MG132
(50 lM) or were co-incubated with 50 lMMG132 and 5 lMmitoxantrone for 2 h. After 2 h mitoxantrone was removed, but MG132 was maintained in cell incubations that
initially contained it. Levels of TOP2A and TOP2B DNA complexes at 0, 1, 3, 6 h after mitoxantrone removal (wash-out) were determined using the TARDIS assay and an
additional time point of 24 h for TOP2A. Statistical comparisons were made between the levels of TOP2-DNA complexes in the presence or absence of MG132 by unpaired t-
test. Figures are given below for cell viability (trypan blue exclusion) under the cell treatment conditions used: ‘‘120 min” refers to the time at which drugs were first added
to cells, ‘‘0” refers to the time at which mitoxantrone wash-out was performed and ‘‘1, 3, 6 h” refers to time post drug wash-out.
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well as reducing the processing itself.
We have shown that inhibition of proteasomal activity
potentiates the growth inhibitor effect of various TOP2 poisons in
a myeloid and a lymphoblastic leukaemia cell line model. This
potentiation is likely to involve increased accumulation and/or
decreased clearing of TOP2 DNA complexes, although other mech-
anisms may also be involved. These findings support the notion
that targeting the ubiquitin proteasome system in combination
with existing therapies may be a productive approach. Further-
more, this may allow lower doses of anti-topoisomerase II drug
to be used, which could potentially reduce unwanted genotoxic
side effects, such as the occurrence of secondary leukaemias.
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